netFormulary NHS
South Staffordshire Joint Formulary
Cannock Chase Clinical Commissioning Group
East Staffordshire Clinical Commissioning Group
South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group
Stafford and Surrounds Clinical Commissioning Group
 Introduction

Preferred prescribing list for South Staffordshire CCG's

Useful Links

BNFSPC  Area Prescribing Group Minutes CCG Patient Group Directions and Patient Specific Directions Prescribing Commissioning and over the counter
Policies
Feedback To Us Link
BNF For Children New Medicines Committee Documents CCG Newsletters NHS England Patient Group Directions    High Cost Drugs
MHRA Drug Safety Updates Decline To Prescribe Form Vaccine Update Prescribing Audits  Communications and drug discontinuations
Care Home Prescribing Resourses Cross Border prescribing guideline     

Covid-19 

Interim Clinical Information 

RICaDs and ESCAs
RICaDs MPFT Mental Health Essential Shared Care Agreements
Clinical Formularies and Guidelines
Area Prescribing Group Guidelines Woundcare Formulary Antimicrobial Guidance Continence Prescribing Formulary
CCG Formularies
North Staffs Joint Formulary Birmingham and Surrounds Formulary Derbyshire Formulary  Wolverhampton Formulary

 

News Feed

09/02/2021 Updated email address for MPFT Rheumatology team

The Midlands Partnership NHS Foundation Trust (MPFT) has notified the Staffordshire CCG’s Medicines Optimisation Team that the email address for contacting the Rheumatology Specialist teams regarding shared-care agreements (ESCAs) used in North Staffordshire has been updated.

The new email address

This replaces

Haywoodrheumatology.ESCA@nhs.net

 

haywoodrheumatology@esca.nhs.net

HaywoodRheumatology@esca.nhs.uk

 

All queries relating to the use of the MPFT’s rheumatology ESCAs i.e. drug monitoring, dose review, specialist input etc., can be directed to the new email above or the helpline telephone number: 01782 673687

 


10/12/2020: New ESCAs in North Staffordshire

Two ESCAs were approved by the Area Prescribing Committee (North) in September 2020 for use in North Staffordshire. They are:

  • Methotrexate for the treatment of Autoimmune Rheumatic diseases (Version 4.1)- This was updated to include additional monitoring information if prescribed concurrently with Leflunomide.
  • Tizanidine for the treatment of spasticity associated with brain injuries, multiple sclerosis or spinal cord injury or disease (Version 1.0)- This is a new ESCA developed by MPFT.

Note that both drugs have an ‘Amber-E’ status on the North Staffs formulary for the relevant indications, thus transfer of prescribing into primary care MUST be accompanied by an agreed ESCA form.

All APC approved ESCAs for the North are available on netFormulary via the link: http://www.northstaffordshirejointformulary.nhs.uk/docs/esca/

For any prescribing-related issues, please contact the respective medicines optimisation team.


3/11/2020 PRODUCT DISCONTINUATION:

Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen (exenatide once-weekly) will be discontinued from 31/12/2020. Clinicians should note that the old device is being replaced by the Bydureon BCise pen (exenatide 2mg prolonged-release injectable suspension); a once weekly, single use, fixed dose pen with a hidden needle that automatically injects the required dose, allowing for simpler administration compared to the old Bydureon device. Prior to prescribing and administration of this new device, patient and caregivers training must be undertaken by a healthcare professional


7/10/20 Smoking Cessation Information Update

Everyone Health, the service provider for smoking cessation service confirms it is now open to all tobacco smokers, living anywhere in Staffordshire, aged 40 years and over. Referrals can still be made by calling the contact centre on 0333 005 0095, or via email: eh.staffs@nhs.net


4/8/20 Updated Gluten-Free Prescribing policy 2020

The updated Gluten-Free Prescribing policy 2020 can be found on the Homepage, Area Prescribing Group Guidelines link, BNF Chapter 9 Nutrition and Blood – Gluten Free prescribing on the South Staffordshire Joint Formulary.


24/7/2020 - Updated Rheumatology ESCA’s

Midlands Partnership NHS Foundation Trust (MPFT) have updated their contact details for their Rheumatology ESCA’s to reflect their dedicated email address:haywoodrheumatology@esca.nhs.net

The updated documents can be found on the ESCA’s link on the North Staffordshire Joint Formulary Home page.


>>> more news

HOW TO USE

  1. The Preferred Prescribing List for the various therapeutic sections of  the British National Formulary (BNF) can be accessed via the links

   2.     PDF How to use guide

   3.   Drugs are colour coded according to the following criteria:

 

Status Description
Red Drugs which require special consideration. These are drugs for Consultant Prescribing ONLY. They should not be prescribed in Primary Care.  
Amber Drugs that should be initiated by a Specialist but are suitable for continuation in Primary Care. For some drugs there may be a Ricad in place to aid the transition to primary care.  
Amber E Drugs that should be initiated by a Specialist but are suitable for continuation in Primary Care but also require and ESCA (Shared Care Agreement)
Green Suitable first-line drugs for implementation in Primary Care  
Green Formulary South Staffs Formulary Choice

NetFormulary
   Visits = 267259
   Last updated: 26/02/2021 10:40:56..